Clinical Trial: Effects of pre-exercise protein ingestion on performance and executive function (Japan)

Tokyo, Aug. 22 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000062645) titled 'Effects of pre-exercise protein ingestion on performance and executive function' on Aug. 21.

Study Type: Interventional

Study Design: Basic Design - Cross-over Randomization - Randomized Blinding - Open -no one is blinded Control - Placebo

Primary Sponsor: Institute - Niigata University of Health and Welfare

Condition: Condition - Healthy adults Classification by malignancy - Others Genomic information - NO

Objective: Narrative objectives1 - This study aims to clarify the effects of pre-exercise protein ingestion on performance in resistance and endurance exercise, and on executive function after exercise. Basic objectives2 - Efficacy

Intervention: Interventions/Control_1 - A single dose of whey protein (SAVAS Aqua Whey Protein 100, Meiji Co., Ltd.) equivalent to 0.4 g of protein per kilogram of body weight (approximately 0.56 g of powder per kilogram, up to a maximum of 56 g of powder per dose), dissolved in 400 mL of water, is ingested 60 minutes before exercise. The exercise task starts 60 minutes after ingestion. Interventions/Control_2 - Only 400 mL of water is ingested 60 minutes before exercise. The same exercise task as in the protein arm starts 60 minutes after ingestion. The two conditions are administered in a randomized crossover order, with an interval of at least one week between conditions.

Eligibility: Age-lower limit - 18 years-old = Gender - Male and Female Key inclusion criteria - Healthy adults affiliated with Niigata University of Health and Welfare. Aged 18 to 30 years. Both sexes are eligible. Not restricted from exercising by a physician. Provided written informed consent after receiving an explanation of the study. Key exclusion criteria - Individuals in poor physical condition (fever of 38 or higher, marked palpitations, shortness of breath, severe fatigue, or cold sweat). Individuals diagnosed at a health checkup with hypertension (resting blood pressure of 180/110 mmHg or higher), heart disease, or an infectious disease. Individuals with a history of cardiovascular disease, an orthopedic or neurological disorder requiring exercise restriction, or a serious medical condition currently under treatment, or who have been advised by a physician to restrict exercise. Individuals with an allergy to milk, dairy products, or soy. Individuals with a history of kidney disease. Individuals who habitually take protein supplements. Individuals with color vision deficiency. Target Size - 48

Recruitment Status: Recruitment status - Preinitiation Date of protocol fixation - 2026 Year 08 Month 21 Day Anticipated trial start date - 2026 Year 09 Month 01 Day Last follow-up date - 2029 Year 03 Month 31 Day

To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000071706

Disclaimer: Curated by HT Syndication.